Shah SJ, Krumholz HM , Reid KJ, Rathore SS, Mandawat A, Spertus JA, Ross JS
Market Size and Forecast Market Size in 2025: USD 60.6 Billion Market Size by 2035: USD 307 Billion CAGR: 17.61% from 2026 to 2035 Base Year: 2025 Forecast Period: 2026-2035 Historical Data: 2022-2024 To Get more information on GLP-1 Receptor Agonist Market - Request Free Sample Report GLP-1 Receptor Agonist Market Trends Oral GLP-1 formulations led by Novo Nordisk's Rybelsus and Eli Lilly's orforglipron in development are expanding the patient population who will accept GLP-1 therapy by removing the injection barrier that constrains current market penetration
S., Arora, J
PlexusDx Tirzepatide Injection (at $289/mo month-to-month, or from $249/mo on the 6-month plan) works alongside oral contraceptives when timing and monitoring are optimized
"Once-weekly semaglutide in adults with overweight or obesity." NEJM, 2021.
2 Although the pancreatic effects of GLP-1 (glucose-dependent insulin secretion and glucagon suppression) are well-established, its extrapancreatic actions are increasingly being recognised as critical to the therapeutic effects of GLP-1RAs
